LLY Sep 2024 420.000 call
| Previous Close | 334.77 |
| Open | N/A |
| Bid | 356.00 |
| Ask | 364.80 |
| Strike | 420.00 |
| Expire Date | 2024-09-20 |
| Day's Range | 334.77 - 334.77 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 5 |
Yahoo FinanceNovo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
BloombergAmgen Soars After CEO Gives Update on Experimental Obesity Drug
(Bloomberg) -- Amgen Inc.’s shares soared in late trading after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide. Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesBiden Calls Ally Japan ‘Xenophobic’ Along With China, RussiaUS and Saudis Near Defense
ZacksEarnings Season: 3 Companies Boosting Guidance
Earnings season continues to chug along, with results from many companies already delivered. And concerning positivity, all three of these companies' report fit the criteria, lifting outlooks following the results.
